C
Calidi Biotherapeutics, Inc. (CLDI)
ASE – Real Time Price. Currency in USD
0.27
-0.01 (-3.75%)
At close: Mar 27, 2026, 3:59 PM EDT
0.27
-0.00 (-1.00%)
After-hours: Mar 27, 2026, 7:55 PM EDT
Get all premium features to the best stock analysis tool
ASE – Real Time Price. Currency in USD
0.27
-0.01 (-3.75%)
At close: Mar 27, 2026, 3:59 PM EDT
0.27
-0.00 (-1.00%)
After-hours: Mar 27, 2026, 7:55 PM EDT
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States. Its product pipeline comprises CLD-101, which is in Phase 1b/2 clinical trial for the treatment of high-grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck squamous cell carcinoma, and soft tissue sarcoma, which is in pre-clinical studies; CLD-301 for multiple indications, which is in preclinical studies; and CLD-400 for certain lung cancer and metastatic solid tumors. The company also offers oncolytic virus platforms, such as NeuroNova, SuperNova, and RTNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.
| Name | Position |
|---|---|
| Dr. Antonio Fernandez Santidrian Ph.D., Pharm.D. | Head of Technical Operations & Chief Scientific Officer |
| Dr. Eric E. Poma Ph.D. | CEO & Director |
| Dr. Guy Travis Clifton M.D. | Chief Medical Officer |
| Mr. Andrew C. Jackson | CFO & Corporate Secretary |
| Date | Type | Document |
|---|---|---|
| 2026-03-11 | 8-K | form8-k.htm |
| 2026-03-05 | S-3MEF | forms-3mef.htm |
| 2026-01-29 | 8-K | form8-k.htm |
| 2025-11-13 | 10-Q | form10-q.htm |
| 2025-11-10 | 8-K | form8-k.htm |
| 2025-10-31 | 8-K | form8-k.htm |
| 2025-10-24 | 8-K | form8-k.htm |
| 2025-09-19 | 8-K | form8-k.htm |
| 2025-08-29 | 8-K | form8-k.htm |
| 2025-08-22 | 8-K | form8-k.htm |